Loyal is developing the first-ever drugs intended to extend the healthspan and lifespan of dogs.
Loyal is developing the first-ever drugs intended to extend the healthspan and lifespan of dogs.
What they do: End-to-end digital patient engagement platform (Care Activation Platform) for health systems
Founded: 2015 (Atlanta, Georgia)
Recent funding: Series B $33.5M (closed July 22, 2024)
Leadership: Founder & CEO: Chad Mallory
Patient engagement and digital front door solutions for health systems
2015
Healthcare technology / Digital patient engagement
$12.5M
$33.5M
Round included support from existing investor Concord Health Partners and multiple strategic investors
“Concord Health Partners (lead or existing investor across rounds)”